Literature DB >> 11074522

Novel amplification unit at chromosome 3q25-q27 in human prostate cancer.

H P Sattler1, R Lensch, V Rohde, E Zimmer, E Meese, H Bonkhoff, M Retz, T Zwergel, A Bex, M Stoeckle, B Wullich.   

Abstract

BACKGROUND: In prostate carcinoma, amplification of the genes c-MYC, Her2/NEU, and the androgen receptor gene has been documented, with gene amplification being related to progressive tumor growth. Recently, using comparative genomic hybridization (CGH), we provided evidence for DNA copy number gains at chromosome 3q25-q26 in prostate cancer [Sattler et al.: Prostate 39:79-86, 1999].
METHODS: In this study, additional prostatic tumors were evaluated by CGH to determine the frequency of DNA overrepresentation at 3q. Comparative PCR and Southern blot analyses were applied to determine whether known genes are involved in DNA copy number gains.
RESULTS: By CGH, DNA copy number gains, all of which involved chromosome region 3q25-q26, were disclosed in 50% of the prostate tumors analyzed. There was no evidence for high-level amplification. The analysis of 12 genes from 3q25-q27 by comparative PCR revealed amplification in 6 (35.3%) of 17 tumors tested. Amplification was detected for the genes IL12A, MDS1, SLC2A2, and SOX2, with coamplification of three genes in two tumors. IL12A was amplified as single gene in three tumors and in a subline of the DU145 cell line, SLC2A2 in one tumor.
CONCLUSIONS: Our studies revealed a novel amplification unit at 3q25-q27 in prostate carcinoma, with the genes IL12A, MDS1, SLC2A2, and SOX2 being located within the amplification unit. A common region of amplification was evident spanning the IL12A gene locus at 3q25-q26.2. Possibly, IL12A indicates an adjacent, till now unidentified gene which is important in the development of prostate cancer. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 11074522     DOI: 10.1002/1097-0045(20001101)45:3<207::aid-pros2>3.0.co;2-h

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  31 in total

1.  DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma.

Authors:  Karine Pallier; Aurélie Cazes; Laila El Khattabi; Cristina Lecchi; Marine Desroches; Claire Danel; Marc Riquet; Elizabeth Fabre-Guillevin; Pierre Laurent-Puig; Hélène Blons
Journal:  Tumour Biol       Date:  2011-10-11

2.  Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients.

Authors:  V Balachandar; B Lakshman Kumar; K Sasikala; P Manikantan; R Sangeetha; S Mohana Devi
Journal:  J Zhejiang Univ Sci B       Date:  2007-09       Impact factor: 3.066

Review 3.  The p53 target Wig-1: a regulator of mRNA stability and stem cell fate?

Authors:  A Vilborg; C Bersani; M T Wilhelm; K G Wiman
Journal:  Cell Death Differ       Date:  2011-03-11       Impact factor: 15.828

4.  Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis.

Authors:  Claire L Simpson; Cheryl D Cropp; Tiina Wahlfors; Asha George; Marypat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Teuvo Tammela; Johanna Schleutker; Joan E Bailey-Wilson
Journal:  Eur J Hum Genet       Date:  2012-09-05       Impact factor: 4.246

5.  Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study.

Authors:  Tamra E Meyer; Eric Boerwinkle; Alanna C Morrison; Kelly A Volcik; Maureen Sanderson; Ann L Coker; James S Pankow; Aaron R Folsom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

6.  HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.

Authors:  Nazanin Sharifi; Arash Salmaninejad; Samira Ferdosi; Abolfazl Nesaei Bajestani; Malihe Khaleghiyan; Mehrdad Asghari Estiar; Mansour Jamali; Mohammad Reza Nowroozi; Abbas Shakoori
Journal:  Oncol Lett       Date:  2016-10-10       Impact factor: 2.967

7.  Zinc induces cell cycle arrest and apoptosis by upregulation of WIG-1 in esophageal squamous cancer cell line EC109.

Authors:  Wei Guo; Ying-Bo Zou; Yao-Guang Jiang; Ru-Wen Wang; Yun-Ping Zhao; Zheng Ma
Journal:  Tumour Biol       Date:  2011-05-11

8.  Evidence that SOX2 overexpression is oncogenic in the lung.

Authors:  Yun Lu; Christopher Futtner; Jason R Rock; Xia Xu; Walter Whitworth; Brigid L M Hogan; Mark W Onaitis
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

9.  Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.

Authors:  Meera Nanjundan; Kwai Wa Cheng; Fan Zhang; John Lahad; Wen-Lin Kuo; Rosemarie Schmandt; Karen Smith-McCune; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 6.603

10.  Ecotropic viral integration site 1, a novel oncogene in prostate cancer.

Authors:  A Queisser; S Hagedorn; H Wang; T Schaefer; M Konantz; S Alavi; M Deng; W Vogel; A von Mässenhausen; G Kristiansen; S Duensing; J Kirfel; C Lengerke; S Perner
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.